Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Postgraduate Medical Journal
|
August 4, 2012
Early clinical implications of microalbuminuria in patients with acute ischaemic stroke
Bang-Hoon Cho, Joon-Tae Kim, Jane Chang, et al.
Gynecologic Oncology
|
December 27, 2023
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population
Emily M Webster, Muhammad Danyal Ahsan, Amita Kulkarni, et al.
JAMA Network Open
|
May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma
Neil J Shah, Yaa Ababio, Anthony Eccleston, et al.
European Urology
|
June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
European Urology Oncology
|
June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
Neal D Shore, Michael S Broder, Pedro C Barata, et al.
Journal of Microbiological Methods
|
October 12, 2021
Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosa
Renee Nicole Ng, Lucinda Jane Grey, Andrew Vaitekenas, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Clinical Genitourinary Cancer
|
April 23, 2024
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Priyanka J Bobbili, Jasmina Ivanova, David B Solit, et al.
The Lancet. Oncology
|
June 3, 2023
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
Madeline Pe, Ahu Alanya, Ragnhild Sorum Falk, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Postgraduate Medical Journal
|
August 4, 2012
Early clinical implications of microalbuminuria in patients with acute ischaemic stroke
Bang-Hoon Cho, Joon-Tae Kim, Jane Chang, et al.
Gynecologic Oncology
|
December 27, 2023
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population
Emily M Webster, Muhammad Danyal Ahsan, Amita Kulkarni, et al.
JAMA Network Open
|
May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma
Neil J Shah, Yaa Ababio, Anthony Eccleston, et al.
European Urology
|
June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
European Urology Oncology
|
June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
Neal D Shore, Michael S Broder, Pedro C Barata, et al.
Journal of Microbiological Methods
|
October 12, 2021
Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosa
Renee Nicole Ng, Lucinda Jane Grey, Andrew Vaitekenas, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Clinical Genitourinary Cancer
|
April 23, 2024
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Priyanka J Bobbili, Jasmina Ivanova, David B Solit, et al.
The Lancet. Oncology
|
June 3, 2023
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
Madeline Pe, Ahu Alanya, Ragnhild Sorum Falk, et al.
Page
of 9